3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
4
Prostatic Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
pembrolizumab
26
Paclitaxel
22
Oxaliplatin
20
Nivolumab
16
Docetaxel
16
Capecitabine
16
Cisplatin
15
Fluorouracil
11
Cyclophosphamide
11
fludarabine
10
S 1 (combination)
10
Trastuzumab
9
Irinotecan
9
Carboplatin
8
Leucovorin
7
tislelizumab
6
aldesleukin
5
Ramucirumab
5
Interleukin-2
5
Gemcitabine
5
Drug Therapy
5
Bevacizumab
5
sintilimab
4
fludarabine phosphate
4
apatinib
4
Radiotherapy
4
Everolimus
4
regorafenib
3
olaparib
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Stomach Neoplasms
×
rucaparib
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled